智通财经APP获悉,招银国际发布研报称,康方生物(09926)2024年业绩反映强劲的成本控制。期内总收入为21亿元人民币,其中产品销售收入20亿元人民币,同比增长25%。该行预计,康方生物今年的产品销售将同比增长60%至33亿元人民币,受惠今年初AK104和AK112被纳入中国国家医保。该行将其目标价上调至102.61港元,维持“买入”评级。
更多港股重磅资讯,下载智通财经app
更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.